Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Maternal exposure timing unspecified? 402 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 402 reports of Maternal exposure timing unspecified have been filed in association with RITUXIMAB (Rituxan). This represents 0.2% of all adverse event reports for RITUXIMAB.

402
Reports of Maternal exposure timing unspecified with RITUXIMAB
0.2%
of all RITUXIMAB reports
242
Deaths
274
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From RITUXIMAB?

Of the 402 reports, 242 (60.2%) resulted in death, 274 (68.2%) required hospitalization, and 239 (59.5%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 402 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Maternal exposure timing unspecified?

METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301) OXYCODONE (300)

Which RITUXIMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified RITUXIMAB Demographics